Pierre A. MORGON is CEO of MRGN Advisors and Regional Partner for Switzerland at Mérieux Développement. He is Chairman of the Board of Virometix, as well as Non-Executive Director to the Boards of Theradiag, of Eurocine Vaccines, and of Vaccitech. Pierre has over 30 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies. He is a lecturer in several MBA programs in world-class business schools and in life science conferences, and at the Mass Challenge biotechnology incubator in Switzerland. He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD and IMD.
Giulio Tarro graduated from Medicine School, Naples University (1962), Italy. Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus (2006). Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). President, Foundation de Beaumont Bonelli for Cancer Research. His basic researches have been concerned with antigens induced early during the replication cycle of human herpesviruses. Another study has involved the identification, isolation, and characterization of specific virus-induced tumor antigens, which were the "fingerprints" left behind in human cancer. Achievements include patents in a field; a discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor-associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.
Medical and cosmopolitan professional specialized in infectious diseases, internal medicine covering various therapeutic axes, certified in Immunology and Pediatric, MBA vaccinology and years of clinical practice contributing to bring innovative science and diplomacy for global health. Lived multi-country medical “field “experience in Southeast Asia (India in particular), West/Central/East Europe. Speaking French, English, Russian, Italian, Czech, Slovak with notion of Mandarin. Over 15 years of experience in pharmaceutical research and development for European and USA companies (Director of R&D for new delivery platforms focused on children and elderly) for various therapeutic areas for adults and children including neurodegenerative diseases, infectious diseases, metabolic diseases and orphan indications. Active member of French immunology society (SFI) administrative board and several international academic societies (focus on innovation of R&D reflecting immunology and genetic variability, role of immunologic approach for treatment and diagnostic, tackle problem of resistance for antimicrobials, antimalarial, antivirals etc.). Member of advisory Health concern (India) and think tank group in order to attract attention to role of immunology, personalized and preventive medicine and accurate diagnostic and global cooperation in this area. Years of expertise to work globally within Europe, USA but recently more focused on BRICS - Asia (India in Particular) as a Medical advisor bringing new innovative concepts alive and getting them endorsed.
Assc. Professor Zelalem was born in Ethiopia. He earned a Ph.D. in Immunology, MBBS Degree in medicine and surgery, a bachelor’s degree in Nursing and Health administration, a bachelor’s degree in Theology and Leadership; a diploma in advanced research proposal writing, research report writing, methods, grant proposal writing. He is Ass. Professor at the Addis Ababa Institute of Technology and Owner, Founder and General Director at United States of African Health Organization “US-AHO” Zelalem is an energetic, motivating and highly skilled consultant specializing in biomedical research particularly in Immunological research and leadership at United States of Africa Health Organization “US-AHO”. His background includes more than 15 years of experience as an educator, clinician, Leadership and advanced biomedical research in all settings in which biomedical research is provided. Zelalem is an Owner, founder, General Director and serves as, General Director of the United States of African Health Organization “US-AHO”. Publications he has made 120+ publications, he is corresponding / first author on 112+ Publications as well as over 44,000 citations.
AW by his profession is biotechnologist and associate professor for molecular biology at the University of Natural Resources and Applied Life Sciences, Vienna. Working from 1995-2004 at the Children’s Cancer Research Institute, Vienna he is experienced in human molecular genetic diagnostics and specialized on diagnostic-testing of syndromal and hereditary neoplastic disease. In 2001 AW obtained the post-doctoral graduation “Specialist in Human Genetics”. Since 2004 at the Molecular Diagnostics business-unit of the AIT-Austrian Institute of Technology he specialized on DNA-methylation- and autoantibody -biomarker development using microarray and high throughput technologies. This research is supported by the Austrian Research Promotion Agency (FFG; Project: RSA PepPipe) and EU H2020 funded project ULTRPLACAD (Grant Agreement no.: 633937).
Tilahun Yilma is a Distinguished Professor of Virology at UC Davis. He is noted for developing what the journal Nature described as one of the two outstanding vaccinia virus recombinant vaccines in the world. He is also noted for developing a method for enhancing the safety and efficacy of recombinant vaccines with the use of cytokines as attenuating and adjuvant genes. Yilma has received many national and international awards for his research contributions. He is also a member of the US National Academy of Sciences and a Fellow of the American Academy of Microbiology.
Zlatko Dembic (M.D., Ph.D.) is a professor of immunology, cell-biology and microbiology at the University of Oslo. He has been working in science at various institutions in Academia (Medical Faculty, Zagreb, Croatia; Max-Planck Institute for Immunogenetics, Tubingen, Germany; Basel Institute for Immunology, Switzerland; Institute of Immunology, Oslo, Norway) and industry (Roche, Switzerland). He has his expertise in molecular biology shown by over 100 publications to date and a monograph about cytokines in immunology. He is co-inventor of the US patent (Roche) covering the production and use of etanercept (Enbrel), which is a successful (anti-TNF) biological used to treat several autoimmune diseases including rheumatoid arthritis. He was the president of the Norwegian Society for Immunology and Editor-in-chief of the Scand J Immunol (at present, associate editor). He is a visiting professor of medicine at the Medical School in his hometown Rijeka (Croatia).
MARIAM IDD MAKAME is currently the Managing Director of Meshurap African Handmade and the Executive Director of Usaidizi Orphans Organization (Lushot, Tanga, Tanzania. Duly recognized by the Tanzania National NGO Coordination (TNNC) Cert. No. ooNGO/08297). Usaidizi Orphans Organization (UOO) is dedicated to providing Food, FREE Health-care, Tuition FREE Education and Shelter to HIV&AIDS infected and/or affected Children. UOO is not limited to supporting only HIV&AIDS Orphans. In our care, we have widows and/or single-mothers, the elderly, and the handicapped and/or disabled members of our community.
Henry M. Sobell completed his studies at Brooklyn Technical High School (1948- 1952), Columbia College (1952-1956), and the University of Virginia School of Medicine (1956-1960). Instead of practicing clinical medicine, he then went to the Massachusetts Institute of Technology (MIT) to join Professor Alexander Rich in the Department of Biology (1960-1965), where, as a Helen Hay Whitney Postdoctoral Fellow, he learned the technique of single crystal X-ray analysis. He then joined the Chemistry Department at the University of Rochester, having been subsequently jointly appointed to both the Chemistry and Molecular Biophysics departments (the latter at the University of Rochester School of Medicine and Dentistry), becoming a full tenured Professor in both departments (1965-1993). He is now retired and living in the Adirondacks in New York, USA.
Prof. Dr. Nerin N. Bahceciler was born in 1965, Melbourne, Australia. Education background: • MD: Istanbul University Cerrahpasha Medical School, Turkey(1983-1989). • Specialist on Pediatrics: Sisli Etfal Government Hospital, Istanbul(1990-1994) • Specialist of Allergy & Immunology: Marmara University, Istanbul, Division of Pediatric Allergy and Immunology(1995-1999). • Associate Proffessor; Marmara University, Istanbul, Division of Pediatric Allergy and Immunology(2002) • Proffessor, Marmara University, Istanbul, Division of Pediatric Allergy and Immunology(2007). Prof. Bahceciler has more than100 scientific publications, more than 2000 citations and book chapters in the field of Allergy/Immunology. She had contributed in the Executive Committee of the Turkish Immunology Academy, and had been the director of the “Immunotherapy” group in the Turkish Allergy and Immunology Academy for <10 yrs. Currently, she lives in Cyprus her home country as head of Department of Pediatrics and Division of Allergy & Immunology in Near East University Hospital in Nicosia.
Dr. Emine YAVUZ received her BS degree in Chemistry from Bogazici University; MS degree in Biochemistry from Worcester Polytechnic Institute (WPI); her Ph.D. degree in Immunology from Gazi University School of Medicine in 2017. She is currently working as an academic specialist (researcher) at Advanced Technology Research and Application Center, Selcuk University. Her research interests include immunology, nano-vaccines, biocompatible nano-carriers, and anti-cancer immunotherapies. This study was supported by grants from the Scientific and Technological Research Council of Turkey (TUBITAK Grant 214S652).
Mohammad Hossein Yazdi got his PhD in the field of Pharmaceutical Biotechnology by 2014 from Tehran University of Medical Sciences, School of Pharmacy. His PhD work was about cancer treatment in particular by immunotherapy. He is now Assistant Professor at Biotechnology Research Center and Recombinant Vaccine Research Center of Tehran University of Medical Sciences and pursues his interest in both vaccine and immunotherapy of cancer and infectious diseases. He has published more than 30 papers in reputed journals and has been serving as senior lecturer of advanced immunology and immunotherapy at Tehran University of Medical Sciences.